Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871614/35409/en/Cytokinetics-to-Host-Investor-Event-and-Conference-Call-to-Discuss-the-Primary-Results-From-SEQUOIA-HCM-at-the-European-Society-of-Cardiology-Heart-Failure-2024-Congress.html

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), which are being presented in a Late Breaking Clinical Trial session at Heart Failure 2024, an International Congress of the European Society of Cardiology. The event will be held at the Pestana Palace Lisboa Hotel in Lisbon, Portugal in the Lustiano I room, and simultaneously webcasted online.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.